DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,244 filers reported holding DANAHER CORPORATION in Q2 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $117,601,147 | -6.7% | 470,687 | -6.7% | 1.02% | -11.5% |
Q1 2024 | $126,007,214 | +51.4% | 504,594 | +40.3% | 1.15% | +35.7% |
Q4 2023 | $83,201,200 | +436.4% | 359,649 | +475.2% | 0.85% | +417.7% |
Q3 2023 | $15,511,460 | -56.4% | 62,521 | -57.8% | 0.16% | -55.6% |
Q2 2023 | $35,570,640 | -57.0% | 148,211 | -54.9% | 0.37% | -64.5% |
Q1 2023 | $82,785,562 | -21.6% | 328,462 | -17.5% | 1.04% | -31.3% |
Q4 2022 | $105,623,093 | -14.9% | 397,947 | -17.2% | 1.51% | -22.1% |
Q3 2022 | $124,176,000 | +11.5% | 480,761 | +9.4% | 1.94% | +17.4% |
Q2 2022 | $111,396,000 | +2.2% | 439,396 | +18.2% | 1.65% | +22.4% |
Q1 2022 | $109,001,000 | -39.6% | 371,598 | -32.2% | 1.35% | -33.9% |
Q4 2021 | $180,323,000 | +12.4% | 548,077 | +4.0% | 2.04% | +6.4% |
Q3 2021 | $160,377,000 | +11.8% | 526,794 | -1.5% | 1.92% | +7.3% |
Q2 2021 | $143,454,000 | +25.4% | 534,559 | +5.2% | 1.79% | +9.0% |
Q1 2021 | $114,396,000 | -5.6% | 508,247 | -6.8% | 1.64% | -8.3% |
Q4 2020 | $121,184,000 | +28.0% | 545,528 | +24.0% | 1.79% | +8.9% |
Q3 2020 | $94,700,000 | +7.5% | 439,792 | -11.8% | 1.64% | +9.7% |
Q2 2020 | $88,130,000 | +44.3% | 498,388 | +13.0% | 1.50% | +14.3% |
Q1 2020 | $61,062,000 | +49.9% | 441,168 | +66.2% | 1.31% | +77.6% |
Q4 2019 | $40,748,000 | +87.4% | 265,492 | +76.4% | 0.74% | +78.9% |
Q3 2019 | $21,740,000 | +11.1% | 150,526 | +10.0% | 0.41% | +6.2% |
Q2 2019 | $19,565,000 | +42.5% | 136,898 | +31.7% | 0.39% | +32.4% |
Q1 2019 | $13,727,000 | -4.1% | 103,980 | -25.1% | 0.29% | -14.8% |
Q4 2018 | $14,318,000 | +10.4% | 138,844 | +16.4% | 0.34% | +25.5% |
Q3 2018 | $12,964,000 | +13.5% | 119,305 | +3.1% | 0.27% | +6.2% |
Q2 2018 | $11,421,000 | +3.0% | 115,739 | +2.2% | 0.26% | +0.8% |
Q1 2018 | $11,086,000 | +30.6% | 113,227 | +23.8% | 0.26% | +28.6% |
Q4 2017 | $8,488,000 | +23.2% | 91,443 | +13.9% | 0.20% | +5.9% |
Q3 2017 | $6,888,000 | -2.4% | 80,302 | -4.0% | 0.19% | -6.0% |
Q2 2017 | $7,056,000 | -4.3% | 83,614 | -3.0% | 0.20% | -6.1% |
Q1 2017 | $7,373,000 | +22.9% | 86,198 | +11.9% | 0.21% | +12.1% |
Q4 2016 | $5,997,000 | +1.1% | 77,041 | +1.8% | 0.19% | -4.5% |
Q3 2016 | $5,933,000 | -61.6% | 75,687 | -50.5% | 0.20% | -63.1% |
Q2 2016 | $15,439,000 | +16.2% | 152,866 | +9.2% | 0.54% | +14.2% |
Q1 2016 | $13,285,000 | -7.9% | 140,045 | -9.8% | 0.47% | -8.5% |
Q4 2015 | $14,423,000 | -26.3% | 155,283 | -32.4% | 0.52% | -28.2% |
Q3 2015 | $19,580,000 | – | 229,787 | – | 0.72% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |